Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the 'CLOSE IT (Closed Loop Open SourcE In Type 1 diabetes) trial
Tom Wilkinson,Dunya Tomic,Erin Boyle,David Burren,Yasser Elghattis,Alicia Jenkins,Celeste Keesing,Sonia Middleton,Natalie Nanayakkara,Jonathan Williman,Martin de Bock,Neale D Cohen,Wilkinson,T.,Tomic,D.,Boyle,E.,Burren,D.,Elghattis,Y.,Jenkins,A.,Keesing,C.,Middleton,S.,Nanayakkara,N.,Williman,J.,de Bock,M.,Cohen,N. D.
DOI: https://doi.org/10.1136/bmjopen-2023-078171
IF: 3.006
2024-02-21
BMJ Open
Abstract:Introduction Multiple automated insulin delivery (AID) systems have become commercially available following randomised controlled trials demonstrating benefits in people with type 1 diabetes (T1D). However, their real-world utility may be undermined by user-associated burdens, including the need to carbohydrate count and deliver manual insulin boluses. There is an important need for a 'fully automated closed loop' (FCL) AID system, without manual mealtime boluses. The (Closed Loop Open SourcE In Type 1 diabetes) trial is a randomised trial comparing an FCL AID system to the same system used as a hybrid closed loop (HCL) in people with T1D, in an outpatient setting over an extended time frame. Methods and analysis Randomised, open-label, parallel, non-inferiority trial comparing the Android Artificial Pancreas System (AAPS) AID algorithm used as FCL to the same algorithm used as HCL. Seventy-five participants aged 18–70 will be randomised (1:1) to one of two treatment arms for 12 weeks: (a) FCL—participants will be advised not to bolus for meals and (b) HCL—participants will use the AAPS AID algorithm as HCL with announced meals. The primary outcome is the percentage of time in target sensor glucose range (3.9–10.0 mmol/L). Secondary outcomes include other glycaemic metrics, safety, psychosocial factors, platform performance and user dietary factors. Twenty FCL arm participants will participate in a 4-week extension phase comparing glycaemic and dietary outcomes using NovoRapid (insulin aspart) to Fiasp (insulin aspart and niacinamide). Ethics and dissemination Approvals are by the Alfred Health Ethics Committee (615/22) (Australia) and Health and Disability Ethics Committees (2022 FULL 13832) (New Zealand). Each participant will provide written informed consent. Data protection and confidentiality will be ensured. Study results will be disseminated by publications, conferences and patient advocacy groups. Trial registration numbers ACTRN12622001400752 and ACTRN12622001401741.
medicine, general & internal